单次分割放疗骨转移处方实践审计的项目化比较与传播与人群层面有意义且持久的实践改变相关
该研究基于省级项目数据,比较了2012年审计与教育干预前后单次分割放疗(SFRT)在骨转移患者中的使用情况。2007至2011年干预前SFRT使用率为49.2%,2013至2016年干预后升至58.9%(P < .001),干预后各中心仍存在较大差异(最低35%、最高81%),结论认为项目化比较与传播可达到接近60%的人群使用率。
要点
- 干预后SFRT使用率从49.2%升至58.9%(P < .001),为约10%的持久实践改变。
- 干预后半数中心SFRT处方率集中在55%-58%的较窄范围,但全中心范围仍为35%至81%。
- 最低使用中心也从26%升至35%(P < .001),但中心间差异提示省级标准化仍有提升空间。
核心结论
- 基于审计与教育的干预带来了持久且有意义的约10%实践改变,省级SFRT使用率接近既往推荐的60%基准,但中心间仍存在显著差异,提示省级标准化仍有提升空间。
研究设计与样本
- 2012年对个体医师处方实践进行审计,并将结果呈现给领导者和肿瘤科医生作为增加SFRT的干预;比较2007至2011年(干预前)与2013至2016年(干预后)省级项目中全部31,192例患者的SFRT使用情况。
主要发现
- SFRT使用率从干预前49.2%升至干预后58.9%(P < .001)。
- 2007至2011年各年使用率分别为51%、51%、48%、49%和48%,2013至2016年分别为60%、62%、59%和56%。
- 干预后半数中心SFRT处方率在55%-58%的较窄范围内,但全中心范围仍宽,最低和最高使用中心分别为35%和81%。
- 最低使用中心仍显示显著增加(26%至35%;P < .001)。
关键数值与推荐
- 省级SFRT使用率与既往推荐的60%基准率相似。
临床怎么用
- 原文结论指出,项目化比较与传播SFRT处方实践可实现接近60%的人群SFRT使用率,但中心间显著差异提示省级标准化仍有提升空间。
- 原文结论提出,随着支持对选择性骨转移患者人群采用消融放疗的证据不断出现,未来SFRT的基准率应重新审视。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is ample evidence that single-fraction radiation therapy (SFRT) is as efficacious as more costly and morbid multifraction regimens. We previously demonstrated that an audit-based intervention increased the use of SFRT in all regional cancer centers the following year. However, other investigators have demonstrated that interventions were only associated with a transient 1-year change in prescribing practices. We sought to determine whether our intervention resulted in a more lasting impact. METHODS AND MATERIALS: In 2012, we performed an audit of the prescribing practices of individual physicians, which was then presented to leaders and oncologists as an intervention to increase SFRT. We compared the use of SFRT between 2007 to 2011 (preintervention) and 2013 to 2016 (postintervention) in all 31,192 patients treated in our provincial program. RESULTS: The use of SFRT increased from 49.2% to 58.9% postintervention (P < .001). Rates from 2007 to 2011 were 51%, 51%, 48%, 49%, and 48%, respectively, whereas the postintervention rates from 2013 to 2016 were 60%, 62%, 59%, and 56%, respectively. Postintervention, half of the centers prescribed SFRT in a relatively narrow range (55%-58%). However, across all centers, there was still a broad range, with the lowest and highest users at 35% and 81%, respectively, although the lowest-using center still showed a significant increase (26% to 35%; P < .001). CONCLUSIONS: Our audit and education-based intervention resulted in a lasting and meaningful 10% change in practice. Our provincial rate is similar to that of a previously recommended benchmark rate of 60%, but we continue to see significant variation by center, suggesting further room for improvement in provincial standardization. With emerging evidence in support of ablative radiation therapy for select populations of patients with bone metastases, future benchmark rates of SFRT should be readdressed. However, our data suggest that programmatic comparison and dissemination of SFRT prescribing practices can achieve a population-based SFRT utilization rate near 60%.
引用
- Olson R, Chan M, Minhas N, et al. Programmatic Comparison and Dissemination of an Audit of Single-fraction Radiation Therapy Prescribing Practices for Bone Metastases is Associated with a Meaningful and Lasting Change in Practice on a Population Level. Int J Radiat Oncol Biol Phys. 2018. PMID: 29902558. doi:10.1016/j.ijrobp.2018.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。